Quinazoline derivatives as potential anticancer agents: A patent review (2007 - 2010)

Expert Opinion on Therapeutic Patents

Volumn 22, Issue 3, 2012, Pages 223-252

  Marzaro, Giovanni ^a   Guiotto, Adriano ^a   Chilin, Adriana ^a  

^a UNIVERSITY OF PADOVA   (Italy)

Author keywords

Anticancer compounds; Kinase inhibitors; P53 modulators; Quinazolines

Indexed keywords

AFATINIB; ANTINEOPLASTIC AGENT; AURORA KINASE INHIBITOR; B RAF KINASE INHIBITOR; BARASERTIB; CANERTINIB; CETUXIMAB; DACOMITINIB; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR; HISTONE DEACETYLASE INHIBITOR; LAPATINIB; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; MILCICLIB; N [4 [6 METHOXY 7 (3 MORPHOLINOPROPOXY) 4 QUINAZOLINYLAMINO]PHENYL]BENZAMIDE; NERATINIB; NMSP 937; PAZOPANIB; PHOSPHATIDYLINOSITOL 3 KINASE INHIBITOR; POLO LIKE KINASE INHIBITOR; PROTEIN SERINE THREONINE KINASE INHIBITOR; PROTEIN TYROSINE KINASE; QUINAZOLINE DERIVATIVE; RADIOLIGAND; RAPAMYCIN; TC 28; TOZASERTIB; UNCLASSIFIED DRUG; UNINDEXED DRUG; VANDETANIB; VASCULOTROPIN INHIBITOR; VATALANIB;

ANTINEOPLASTIC ACTIVITY; CANCER CELL CULTURE; CANCER REGRESSION; DIARRHEA; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG ERUPTION; DRUG HALF LIFE; DRUG MECHANISM; DRUG POTENTIATION; DRUG STRUCTURE; DRUG TARGETING; ENZYME INHIBITION; HUMAN; IC 50; LUNG CANCER; LUNG TUMOR; MEDICAL LITERATURE; NONHUMAN; PATENT; REVIEW; THYMUS CANCER; TREATMENT OUTCOME;

ANIMALS; ANTINEOPLASTIC AGENTS; DRUG DELIVERY SYSTEMS; DRUG DESIGN; DRUG DISCOVERY; HUMANS; NEOPLASMS; PATENTS AS TOPIC; PROTEIN KINASE INHIBITORS; QUINAZOLINES;

EID: 84858664241     PISSN: 13543776     EISSN: 17447674     Source Type: Journal    
DOI: 10.1517/13543776.2012.665876     Document Type: Review

References (215)

1. Eguchi S, Eguchi S. Quinazoline Alkaloids and Related Chemistry Bioactive Heterocycles I. Springer Berlin; Heidelberg: 2006. p. 113-56
2. Dempcy RO, Skibo EB. Rational design of quinazoline-based irreversible inhibitors of human erythrocyte purine nucleoside phosphorylase. Biochemistry 1991;30:8480-7
3. Skelton LA, Ormerod MG, Titley J, et al. A novel class of lipophilic quinazoline-based folic acid analogues cytotoxic agents with a folate-independent locus. Br J Cancer 1999;79:1692-701 (Pubitemid 29132291)
4. Scanlon KJ, Moroson BA, Bertino JR, Hynes JB. Quinazoline analogues of folic acid as inhibitors of thymidylate synthetase from bacterial and mammalian sources. Mol Pharmacol 1979;16:261-9 (Pubitemid 9223422)
5. Oatis JE Jr, Hynes JB. Synthesis of quinazoline analogues of folic acid modified at position 10. J Med Chem 1977;20:1393-6 (Pubitemid 8209546)
6. Davoll J, Johnson AM. Quinazoline analogues of folic acid. J Chem Soc 1970;8:997-1002
7. Martin GJ, Moss J, Avakian S. Folic acid activity of N-(4-(4-quinazoline) -benzoyl) glutamic acid. J Biol Chem 1947;167:737
8. Cavalli A, Lizzi F, Bongarzone S, et al. Complementary medicinal chemistry-driven strategies toward new antitrypanosomal and antileishmanial lead drug candidates. FEMS Immunol Med Microbiol 2010;58:51-60
9. Chevalier J, Mahamoud A, Baitiche M, et al. Quinazoline derivatives are efficient chemosensitizers of antibiotic activity in Enterobacter aerogenes, Klebsiella pneumoniae and Pseudomonas aeruginosa resistant strains. Int J Antimicrob Agents 2010;36:164-8
10. Elslager EF, Davoll J, Jacob P, et al. Folate antagonists. 12. Antimalarial and antibacterial effects of 2,4-diamino-6- [(aralkyl and alicyclid)thio-, sulfinyl-, and sulfonyl]quinazolines. J Med Chem 1978;21:639-43 (Pubitemid 8368325)
11. Elslager EF, Jacob P, Johnson J, et al. Folate antagonists. 13. 2,4-Diamino-6-] (alpha,alpha,alpha-trifluoro-m-tolyl)thio] quinazoline and related 2,4-diamino-6- [(phenyl- and naphthyl)thio]quinazolines, a unique class of antimetabolites with extraordinary antimalarial and antibacterial effects. J Med Chem 1978;21:1059-70 (Pubitemid 9029082)
12. Rohini R, Shanker K, Reddy PM, et al. Mono and bis-6-arylbenzimidazo[1,2- c] quinazolines: a new class of antimicrobial agents. Eur J Med Chem 2009;44:3330-9
13. Desai NC, Undavia NK, Trivedi PB, et al. Synthesis and anti-HIV activity of some non-nucleoside 2,3-disubstituted quinazoline derivatives (Part-V). Indian J Exp Biol 1998;36:1280-3
14. Chao Q, Deng L, Shih H, et al. Substituted isoquinolines and quinazolines as potential antiinflammatory agents. Synthesis and biological evaluation of inhibitors of tumor necrosis factor alpha. J Med Chem 1999;42:3860-73 (Pubitemid 29453467)
15. El-Bendary ER, el-Ashmawy MB, Barghash AM, et al. Synthesis of some new quinazolines and quinoxalines of potential antiinflammatory activity. Boll Chim Farm 1996;135:617-20 (Pubitemid 27401514)
16. Jindal DP, Bhatti RS, Ahlawat S, Gupta R. Synthesis and bronchodilatory activity of some nitrogen bridgehead compounds. Eur J Med Chem 2002;37:419-25 (Pubitemid 34465551)
17. Combs DW, Rampulla MS, Russell RK, et al. Design, synthesis and bronchodilatory activity of a series of quinazoline-3-oxides. Drug Des Deliv 1990;6:241-54 (Pubitemid 20349922)
18. Chen Z, Hu G, Li D, et al. Synthesis and vasodilator effects of rutaecarpine analogues which might be involved transient receptor potential Vanilloid subfamily, member 1 (TRPV1). Bioorg Med Chem 2009;17:2351-9
19. Tseng CJ, Chen SY, Tao PL, et al. Antihypertensive effects of AT-112, newly synthesized quinazoline derivative in spontaneously hypertensive rats. Proc Natl Sci Counc Repub China B 1995;19:159-65
20. Uckun FM, Sudbeck EA, Mao C, et al. Structure-based design of novel anticancer agents. Curr Cancer Drug Targets 2001;1:59-71 (Pubitemid 33772175)
21. Rosetti M, Tesei A, Ulivi P, et al. Modulation of drug cytotoxicity by Iressa (ZD1839) in pancreatic cancer cell lines. Cancer Biol Ther 2005;4:1089-95 (Pubitemid 41598562)
22. Ghosh S, Narla RK, Zheng Y, et al. Structure-based design of potent inhibitors of EGF-receptor tyrosine kinase as anti-cancer agents. Anti Cancer Drug Des 1999;14:403-10 (Pubitemid 30168572)
23. Cunningham D, Zalcberg J, Smith I, et al. 'Tomudex' (ZD1694): a novel thymidylate synthase inhibitor with clinical antitumour activity in a range of solid tumours. 'Tomudex' International Study Group. Ann Oncol 1996;7:179-82 (Pubitemid 26096478)
24. Chilin A, Conconi MT, Marzaro G, et al. Exploring epidermal growth factor receptor (EGFR) inhibitor features: the role of fused dioxygenated rings on the quinazoline scaffold. J Med Chem 2010;53:1862-6
25. Marzaro G, Guiotto A, Pastorini G, Chilin A. A novel approach to quinazolin-4(3H)-one via quinazoline oxidation: an improved synthesis of 4-anilinoquinazolines. Tetrahedron 2010;66:962-8
26. Wang C, Li S, Liu H, et al. Copper-catalyzed synthesis of quinazoline derivatives via Ullmann-type coupling and aerobic oxidation. J Org Chem 2010;75:7936-8
27. Yang X, Liu H, Fu H, et al. Efficient copper-catalyzed synthesis of 4-aminoquinazoline and 2,4-diaminoquinazoline derivatives. Synlett 2010;4:101-6
28. Ferrini S, Ponticelli F, Taddei M. Convenient synthetic approach to 2,4-disubstituted quinazolines. Org Lett 2007;9:69-72
29. Moulder SL, Yakes FM, Muthuswamy SK, et al. Epidermal growth factor receptor (HER1) tyrosine kinase inhibitor ZD1839 (Iressa) inhibits HER2/neu (erbB2)-overexpressing breast cancer cells in vitro and in vivo. Cancer Res 2001;61:8887-95 (Pubitemid 34013905)
30. Hanks SK, Hunter T. Protein kinases 6. The eukaryotic protein kinase superfamily: kinase (catalytic) domain structure and classification. Faseb J 1995;9:576-96
31. Manning G, Whyte DB, Martinez R, et al. The protein kinase complement of the human genome. Science 2002;298:1912-34 (Pubitemid 35425239)
32. Liao JJ. Molecular recognition of protein kinase binding pockets for design of potent and selective kinase inhibitors. J Med Chem 2007;50:409-24 (Pubitemid 46239775)
33. Capra M, Nuciforo PG, Confalonieri S, et al. Frequent alterations in the expression of serine/threonine kinases in human cancers. Cancer Res 2006;66:8147-54 (Pubitemid 44299182)
34. Tsatsanis C, Spandidos DA. The role of oncogenic kinases in human cancer (Review). Int J Mol Med 2000;5:583-90
35. Dietrich J, Gokhale V, Wang X, et al. Application of a novel [3 + 2] cycloaddition reaction to prepare substituted imidazoles and their use in the design of potent DFG-out allosteric B-Raf inhibitors. Bioorg Med Chem 2010;18:292-304
36. Davies H, Bignell GR, Cox C, et al. Mutations of the BRAF gene in human cancer. Nature 2002;417:949-54 (Pubitemid 34716871)
37. AstraZeneca AB. Chemical compounds. WO2007071963; 2007
38. AstraZeneca AB. Pyridinylquinazolinamine derivatives and their use as B-Raf inhibitors. WO2008020203; 2008
39. AstraZeneca AB. Chemical compounds-576. WO2008068507; 2008
40. AstraZeneca AB. Substituted quinazoline with anti-cancer activity. WO2007113557; 2007
41. AstraZeneca AB. Chemical compounds. WO2007113558; 2007
42. AstraZeneca AB. Quinazolin-4-one derivatives, process for their preparation and pharmaceutical compositions containing them. WO2007119055; 2007
43. Hennessy BT, Smith DL, Ram PT, et al. Exploiting the PI3K/AKT pathway for cancer drug discovery. Nat Rev Drug Discov 2005;4:988-1004
44. ViVanco I, Sawyers CL. The phosphatidylinositol 3-Kinase AKT pathway in human cancer. Nat Rev Cancer 2002;2:489-501 (Pubitemid 37328931)
45. Converso A, Hartingh T, Garbaccio RM, et al. Development of thioquinazolinones, allosteric Chk1 kinase inhibitors. Bioorg Med Chem Lett 2009;19:1240-4
46. TargeGen, Inc. Thiazolidine compounds, and methods of making and using same. WO2009026346; 2009
47. Smithkline Beecham Corp. Benzodihydroquinazoline as PI3 kinase inhibitors. WO2008086158; 2008
48. Smithkline Beecham Corp. Quinazoline derivatives as PI3 kinase inhibitors. WO2008157191; 2008
49. Hoffmann-La Roche. Quinazoline derivatives as PI3 kinase inhibitors. WO2008152387; 2008
50. Bayer Pharmaceuticals. Substituted 2, 3-dihydroimidazo[1,2-c]quinazoline derivatives useful for treating hyperproliferative disorders and diseases associated with angiogenesis. WO2008070150; 2008
51. Wyeth. 7H-pyrrolo[2,3-h]quinazoline compounds, their use as mTOR kinase and PI3 kinase inhibitors, and their synthesis. WO2009111547; 2009
52. AstraZeneca AB. Chemical compounds. WO2007083096; 2007
53. National Health Research Institute. Fused multicyclic compounds as protein kinase inhibitors. WO2010036629; 2010
54. Harrington EA, Bebbington D, Moore J, et al. VX-680, a potent and selective small-molecule inhibitor of the Aurora kinases, suppresses tumor growth in vivo. Nat Med 2004;10:262-7 (Pubitemid 38667616)
55. Universitat Leipzig. Aurora kinase inhibitors compounds. WO2010081881; 2010
56. Sardon T, Cottin T, Xu J, et al. Development and biological evaluation of a novel aurora A kinase inhibitor. ChemBioChem 2009;10:464-78
57. Girdler F, Gascoigne KE, Eyers PA, et al. Validating aurora B as an anti-cancer drug target. J Cell Sci 2006;119:3664-75 (Pubitemid 44501870)
58. AstraZeneca AB. Combination therapy for the treatment of cancer. WO2007132215; 2007
59. Grundy M, Seedhouse C, Russell NH, Pallis M. P-glycoprotein and breast cancer resistance protein in acute myeloid leukaemia cells treated with the aurora-B kinase inhibitor barasertib-hQPA. BMC Cancer 2011;11:254
60. Mortlock AA, Foote KM, Heron NM, et al. Discovery, synthesis, and in vivo activity of a new class of pyrazoloquinazolines as selective inhibitors of aurora B kinase. J Med Chem 2007;50:2213-24 (Pubitemid 46683074)
61. Mori N, Ishikawa C, Senba M, et al. Effects of AZD1152, a selective aurora B kinase inhibitor, on Burkitt's and Hodgkin's lymphomas. Biochem Pharmacol 2011;81:1106-15
62. Wilkinson RW, Odedra R, Heaton SP, et al. AZD1152, a selective inhibitor of aurora B kinase, inhibits human tumor xenograft growth by inducing apoptosis. Clin Cancer Res 2007;13:3682-8 (Pubitemid 46955132)
63. Walsby E, Walsh V, Pepper C, et al. Effects of the aurora kinase inhibitors AZD1152-HQPA and ZM447439 on growth arrest and polyploidy in acute myeloid leukemia cell lines and primary blasts. Haematologica 2008;93:662-9 (Pubitemid 351669305)
64. Azzariti A, Bocci G, Porcelli L, et al. Aurora B kinase inhibitor AZD1152: determinants of action and ability to enhance chemotherapeutics effectiveness in pancreatic and colon cancer. Br J Cancer 2011;104:769-80
65. Available from: www.clinicaltrial.gov NCT00530699
66. GioVannetti E, Mey V, Nannizzi S, et al. Pharmacogenetics of anticancer drug sensitivity in pancreatic cancer. Mol Cancer Ther 2006;5:1387-95 (Pubitemid 44070474)
67. Chen CJ, Chin JE, Ueda K, et al. Internal duplication and homology with bacterial transport proteins in the mdr1 (P-glycoprotein) gene from multidrug-resistant human cells. Cell 1986;47:381-9 (Pubitemid 17210152)
68. Fischer V, Einolf HJ, Cohen D. Efflux transporters and their clinical releVance. Mini Rev Med Chem 2005;5:183-95 (Pubitemid 40305730)
69. Strebhardt K. Multifaceted polo-like kinases: drug targets and antitargets for cancer therapy. Nat Rev Drug Discov 2010;9:643-60
70. Yuan J, Horlin A, Hock B, et al. Polo-like kinase, a novel marker for cellular proliferation. Am J Pathol 1997;150:1165-72 (Pubitemid 27152634)
71. Ando K, Ozaki T, Yamamoto H, et al. Polo-like kinase 1 (Plk1) inhibits p53 function by physical interaction and phosphorylation. J Biol Chem 2004;279:25549-61 (Pubitemid 38756815)
72. Nerviano Medical Sciences s.r.l. Substituted pyrazolo-quinazoline derivatives, process for their preparation and their use as kinase inhibitors. WO2008074788; 2008
73. Beria I, Bossi RT, Brasca MG, et al. NMS-P937, a 4,5-dihydro-1H-pyrazolo [4,3-h]quinazoline derivative as potent and selective Polo-like kinase 1 inhibitor. Bioorg Med Chem Lett 2011;21:2969-74
74. Beria I, Valsasina B, Brasca MG, et al. 4,5-Dihydro-1H-pyrazolo[4,3-h] quinazolines as potent and selective Polo-like kinase 1 (PLK1) inhibitors. Bioorg Med Chem Lett 2010;20:6489-94
75. Beria I, Ballinari D, Bertrand JA, et al. Identification of 4,5-dihydro-1Hpyrazolo[4,3-h]quinazoline derivatives as a new class of orally and selective Polo-like kinase 1 inhibitors. J Med Chem 2010;53:3532-51
76. Brasca MG, Amboldi N, Ballinari D, et al. Identification of N,1,4, 4-tetramethyl-8-{[4-(4-methylpiperazin- 1-yl)phenyl]amino}-4,5-dihydro- 1Hpyrazolo[ 4,3-h]quinazoline-3- carboxamide (PHA-848125), a potent, orally available cyclin dependent kinase inhibitor. J Med Chem 2009;52:5152-63
77. Degrassi A, Russo M, Nanni C, et al. Efficacy of PHA-848125, a cyclin-dependent kinase inhibitor, on the K-Ras(G12D)LA2 lung adenocarcinoma transgenic mouse model: evaluation by multimodality imaging. Mol Cancer Ther 2010;9:673-81
78. Caporali S, Alvino E, Starace G, et al. The cyclin-dependent kinase inhibitor PHA-848125 suppresses the in vitro growth of human melanomas sensitive or resistant to temozolomide, and shows synergistic effects in combination with this triazene compound. Pharmacol Res 2010;61:437-48
79. Available from: www.clinicaltrial.gov NCT01011439
80. Novartis. Quinazolines for PDK1 inhibition. WO2007117607; 2007
81. Novartis. Quinazoline for PDK1 inhibition. WO2008079988; 2008
82. Merck. Inhibitors of checkpoint kinases. WO2009102537; 2009
83. Cancer Research Technology Ltd. Therapeutic oxy-phenyl-aryl compounds and their use. WO2009053694; 2009
84. Cancer Research Technology. Aminoethyl- amino-aryl (AEAA) compounds and their use. WO2007125331; 2007
85. Novartis AG. Heterocyclic PIM-kinase inhibitors. WO2010026122; 2010
86. Senex Biotechnology. Identification of CDK1 pathway inhibitors. WO2007133773; 2007
87. Feng L, Lograsso P, Bannister T, et al. Quinazoline derivatives as kinase inhibitors. WO2010056758; 2010
88. Merck Patent GMBH. Novel amino azaheterocyclic carboxamides. WO2010093419; 2010
89. Janssen Pharmaceuticals. Use of mt kinase inhibitors for treating or preventing brain cancer. WO2008049901; 2008
90. Krause DS, Van Etten RA. Tyrosine kinases as targets for cancer therapy. N Engl J Med 2005;353:172-87 (Pubitemid 41058349)
91. Paul MK, Mukhopadhyay AK. Tyrosine kinase - role and significance in Cancer. Int J Med Sci 2004;1:101-15
92. Kanda S, Miyata Y, Kanetake H, Smithgall TE. Non-receptor protein-tyrosine kinases as molecular targets for antiangiogenic therapy (Review). Int J Mol Med 2007;20:113-21
93. Brunelleschi S, Penengo L, Santoro MM, Gaudino G. Receptor tyrosine kinases as target for anti-cancer therapy. Curr Pharm Des 2002;8:1959-72 (Pubitemid 34982163)
94. Petrelli A, Giordano S. From single- to multi-target drugs in cancer therapy: when aspecificity becomes an adVantage. Curr Med Chem 2008;15:422-32 (Pubitemid 351472408)
95. Van der Geer P, Hunter T, Lindberg RA. Receptor protein-tyrosine kinases and their signal transduction pathways. Annu Rev Cell Biol 1994;10:251-337 (Pubitemid 24372822)
96. Sirvent A, Benistant C, Roche S. Cytoplasmic signalling by the c-Abl tyrosine kinase in normal and cancer cells. Biol Cell 2008;100:617-31
97. Asim M, Siddiqui IA, Hafeez BB, et al. Src kinase potentiates androgen receptor transactivation function and invasion of androgen-independent prostate cancer C4-2 cells. Oncogene 2008;27:3596-604 (Pubitemid 351793796)
98. Hilbig A. Src kinase and pancreatic cancer. Recent Res Cancer 2008;177:179-85
99. Hiscox S, Jordan NJ, Morgan L, et al. Src kinase promotes adhesion-independent activation of FAK and enhances cellular migration in tamoxifen-resistant breast cancer cells. Clin Exp Metastasis 2007;24:157-67 (Pubitemid 46850227)
100. Dayam R, Grande F, Al-Mawsawi LQ, Neamati N. Recent adVances in the design and discovery of small-molecule therapeutics targeting HER2/neu. Expert Opin Ther Patents 2007;17:83-102 (Pubitemid 46075654)
101. Herbst RS, Langer CJ. Epidermal growth factor receptors as a target for cancer treatment: the emerging role of IMC-C225 in the treatment of lung and head and neck cancers. Semin Oncol 2002;29:27-36 (Pubitemid 34226516)
102. Nishio M, Taguchi F, Ohyanagi F, et al. Gefitinib efficacy associated with multiple expression of HER family in non-small cell lung cancer. Anticancer Res 2006;26:3761-5 (Pubitemid 44701456)
103. Maheswaran S, Sequist LV, Nagrath S, et al. Detection of mutations in EGFR in circulating lung-cancer cells. N Engl J Med 2008;359:366-77
104. Michalczyk A, Kluter S, Rode HB, et al. Structural insights into how irreversible inhibitors can overcome drug resistance in EGFR. Bioorg Med Chem 2008;16:3482-8 (Pubitemid 351484056)
105. Slichenmyer WJ, Elliott WL, Fry DW. CI-1033, a pan-erbB tyrosine kinase inhibitor. Semin Oncol 2001;28:80-5 (Pubitemid 33065113)
106. Rixe O, Franco SX, Yardley DA, et al. A randomized, phase II, dose-finding study of the pan-ErbB receptor tyrosine-kinase inhibitor CI-1033 in patients with pretreated metastatic breast cancer. Cancer Chemother Pharm 2009;64:1139-48
107. Sachdev JC, Jahanzeb M. Blockade of the HER family of receptors in the treatment of HER2-positive metastatic breast cancer. Clin Breast Cancer 2012;12:19-29
108. Ou SH. Second-generation irreversible epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs): A better mousetrap? A review of the clinical evidence. Crit Rev Oncol Hematol 2012; [Epub ahead of print]
109. Gonzales AJ, Hook KE, Althaus IW, et al. Antitumor activity and pharmacokinetic properties of PF-00299804, a second-generation irreversible pan-erbB receptor tyrosine kinase inhibitor. Mol Cancer Ther 2008;7:1880-9
110. Hanmi Pharmaceuticals. Quinazoline derivatives for inhibiting the growth of cancer cell. WO2008002039; 2008
111. Hanmi Pharmaceuticals. Novel amide derivative for inhibiting the growth of cancer cells. WO2008150118; 2008
112. Cha MY, Lee KO, Kim JW, et al. Discovery of a novel Her-1/Her-2 dual tyrosine kinase inhibitor for the treatment of Her-1 selective inhibitor-resistant non-small cell lung cancer. J Med Chem 2009;52:6880-8
113. Universita degli Studi di Parma. Irreversible EGFR inhibitor compounds with antiproliferative activity. WO2010076764; 2010
114. Boehringer Ingelheim International. Quinazoline derivatives for the treatment of cancer disease. WO2007054550; 2007
115. Boehringer Ingelheim International. Method for treating cancer harbouring egfr mutations. WO2008034776; 2008
116. Li D, Ambrogio L, Shimamura T, et al. BIBW2992, an irreversible EGFR/ HER2 inhibitor highly effective in preclinical lung cancer models. Oncogene 2008;27:4702-11
117. Ioannou N, Dalgleish AG, Seddon AM, et al. Anti-tumour activity of Afatinib, an irreversible ErbB family blocker, in human pancreatic tumour cells. Br J Cancer 2011;105:1554-62
118. Eskens FA, Mom CH, Planting AS, et al. A phase I dose escalation study of BIBW 2992, an irreversible dual inhibitor of epidermal growth factor receptor 1 (EGFR) and 2 (HER2) tyrosine kinase in a 2-week on, 2-week off schedule in patients with advanced solid tumours. Br J Cancer 2008;98:80-5
119. Ballou LM, Lin RZ. Rapamycin and mTOR kinase inhibitors. J Chem Biol 2008;1:27-36
120. Perera SA, Li D, Shimamura T, et al. HER2YVMA drives rapid development of adenosquamous lung tumors in mice that are sensitive to BIBW2992 and rapamycin combination therapy. Proc Natl Acad Sci USA 2009;106:474-9
121. Regales L, Gong Y, Shen R, et al. Dual targeting of EGFR can overcome a major drug resistance mutation in mouse models of EGFR mutant lung cancer. J Clin Invest 2009;119:3000-10
122. Available from: www.boehringeringelheim.com/news/news-releases/press- releases/2010/-11-october-2010-oncology.html
123. Boehringer Ingelheim International. Combination treatment of cancer comprising EGFR/HER2 inhibitors. WO2007054551; 2007
124. Available from: www.clinicaltrial.gov NCT01251653
125. AstraZeneca AB. Quinazoline derivatives as anticancer agents. WO2007034143; 2007
126. AstraZeneca AB. 4-(1H-indazol-5- ylamino)quinazoline compounds as ERBb receptor tyrosine kinase inhibitors for the treatment of cancer. WO2007034144; 2007
127. AstraZeneca AB. 4-anilino substituted quinazoline derivatives as tyrosine kinase inhibitors. WO2007063291; 2007
128. AstraZeneca AB. Quinazoline derivatives used as inhibitors of ERBb tyrosine kinase. WO2007063293; 2007
129. Barlaam B, Acton DG, Ballard P, et al. Neutral 5-substituted 4- indazolylaminoquinazolines as potent, orally active inhibitors of erbB2 receptor tyrosine kinase. Bioorg Med Chem Lett 2008;18:1799-803 (Pubitemid 351391850)
130. Boehringer Ingelheim International. Bicyclic heterocycles medicaments comprising said compounds use and method for production thereof. WO2007023073; 2007
131. Boehringer Ingelheim International. Bicyclic heterocycles, medicaments containing these compounds, their use and process for preparating them. WO2007101782; 2007
132. Boehringer Ingelheim International. Bicyclic heterocycles, medicaments containing said compounds, use thereof, and method for production of same. WO2008055854; 2008
133. Boehringer Ingelheim International. Biclycic heterocycles, drugs containing said compounds, use thereof, and methods for production thereof. WO2008095847; 2008
134. Boehringer Ingelheim International. Spirocyclic heterocycles, medicaments containing said compounds, use thereof and method for their production. WO2009098061; 2009
135. Boehringer Ingelheim International. Cyclohexyloxy-substituted heterocyclics, medicines containing these compounds and method for the production thereof. WO2010015522; 2010
136. Boehringer Ingelheim International. Cyclohexyloxy-substituted heterocyclics, medicines containing these compounds and method for the production thereof. WO2010015523; 2010
137. Boehringer Ingelheim International. Method for stereoselective synthesis of bicyclic heterocyclene. WO2010015524; 2010
138. Pennell NA, Lynch TJ Jr. Combined inhibition of the VEGFR and EGFR signaling pathways in the treatment of NSCLC. Oncologist 2009;14:399-411
139. Alferez D, Wilkinson RW, Watkins J, et al. Dual inhibition of VEGFR and EGFR signaling reduces the incidence and size of intestinal adenomas in Apc (Min/+) mice. Mol Cancer Ther 2008;7:590-8 (Pubitemid 351482142)
140. Dutta PR, Maity A. Cellular responses to EGFR inhibitors and their releVance to cancer therapy. Cancer Lett 2007;254:165-77 (Pubitemid 47161103)
141. Hanmi Pharmaceuticals. Quinazoline derivatives as a signal transduction inhibitor and method for the preparation thereof. WO2007055513; 2007
142. Hanmi Pharmaceuticals. Quinazoline derivatives as a multiplex inhibitor and method for the preparation thereof. WO2007055514; 2007
143. Scott EN, Meinhardt G, Jacques C, et al. Vatalanib: the clinical development of tyrosine kinase inhibitor of angiogenesis in solid tumours. Expert Opin Investig Drugs 2007;16:367-79 (Pubitemid 46401662)
144. Sathornsumetee S, Rich JN. Vandetanib, a novel multitargeted kinase inhibitor, in cancer therapy. Drugs Today 2006;42:657-70 (Pubitemid 44901640)
145. Concert Pharmaceuticals. 4-aminoquinazoline derivatives and methods of use thereof. WO2008024439; 2008
146. Concert Pharmaceuticals. Quinazoline derivatives and methods of treatment. WO2008076949; 2008
147. Concert Pharmaceuticals. Vandetanib derivatives. WO2009094210; 2009
148. Concert Pharmaceuticals. Quinazoline compounds and methods of treating cancer. WO2009094211; 2009
149. Concert Pharmaceuticals. Quinazoline derivatives and methods of treatment. WO2009121042; 2009
150. Concert Pharmaceuticals. 4-aminoquinazoline prodrugs. WO2010005585; 2010
151. Auspek Pharmaceuticals. Substituted quinazoline inhibitors of growth factor receptor tyrosine kinases. WO2010028254; 2010
152. DeVita VT, Schein PS. The use of drugs in combination for the treatment of cancer: rationale and results. N Engl J Med 1973;288:998-1006
153. Chefrour M, Milano G, Formento P, et al. Positive interaction between lapatinib and capecitabine in human breast cancer models: study of molecular determinants. Fundam Clin Pharmacol 2011; [Epub ahead of print]
154. Monk BJ, Mas Lopez L, Zarba JJ, et al. Phase II, open-Label study of Pazopanib or Lapatinib monotherapy compared with Pazopanib plus Lapatinib combination therapy in patients with adVanced and recurrent cervical cancer. J Clin Oncol 2010;28:3562-9
155. Smithkline Beecham Corp. Cancer treatment method. WO2007121279; 2007
156. Chu E. The IGF-1R pathway as therapeutic target. Oncology 2011;25:538-9
157. Sleijfer S, Ray-Coquard I, Papai Z, et al. Pazopanib, a multikinase angiogenesis inhibitor, in patients with relapsed or refractory adVanced soft tissue sarcoma: a phase II study from the European organisation for research and treatment of cancer-soft tissue and bone sarcoma group (EORTC study 62043). J Clin Oncol 2009;27:3126-32
158. Smithkline Beecham Corp. Cancer treatment method. WO2007143483; 2007
159. Ushiyama S, Yamada T, Murakami Y, et al. Preclinical pharmacology profile of CS-706, a novel cyclooxygenase-2 selective inhibitor, with potent antinociceptive and anti-inflammatory effects. Eur J Pharmacol 2008;578:76-86 (Pubitemid 350179749)
160. Tragara Pharmaceuticals. Combination therapy for the treatment of cancer using COX-2 inhibitors and dual inhibitors of EGFR (ERBb1) and HER-2 (ERBb2). WO2009042613; 2009
161. Ali S, El-Rayes BF, Sarkar FH, Philip PA. Simultaneous targeting of the epidermal growth factor receptor and cyclooxygenase-2 pathways for pancreatic cancer therapy. Mol Cancer Ther 2005;4:1943-51 (Pubitemid 43056977)
162. Kao J, Sikora AT, Fu S. Dual EGFR and COX-2 inhibition as a novel approach to targeting head and neck squamous cell carcinoma. Curr Cancer Drug Targets 2009;9:931-7
163. Koki AT, Leahy KM, Masferrer JL. Potential utility of COX-2 inhibitors in chemoprevention and chemotherapy. Expert Opin Investig Drugs 1999;8:1623-38 (Pubitemid 29460527)
164. Available from: www.clinicaltrial.gov APRICOT-B, NCT00657137
165. Buzdar AU. Anastrozole (Arimidex)-an aromatase inhibitor for the adjuvant setting? Br J Cancer 2001;85:6-10 (Pubitemid 33753503)
166. AstraZeneca AB. Combination comprising 4-(3-chloro-2-fluoroanilino)- 7-methoxy{[1-(n-methylcarbomethyl) piperidin-4-yl]oxy}quinazoline. WO2009138779; 2009
167. Hickinson DM, Klinowska T, Speake G, et al. AZD8931, an equipotent, reversible inhibitor of signaling by epidermal growth factor receptor, ERBB2 (HER2), and ERBB3: a unique agent for simultaneous ERBB receptor blockade in cancer. Clin Cancer Res 2010;16:1159-69
168. Available from: www.clinicaltrial.gov NCT01151215
169. Thiagalingam S, Cheng KH, Lee HJ, et al. Histone deacetylases: unique players in shaping the epigenetic histone code. Ann NY Acad Sci 2003;983:84-100 (Pubitemid 36399322)
170. Dokmanovic M, Clarke C, Marks PA. Histone deacetylase inhibitors: overview and perspectives. Mol Cancer Res 2007;5:981-9 (Pubitemid 350080267)
171. Cai X, Zhai HX, Wang J, et al. Discovery of 7-(4-(3- ethynylphenylamino)- 7- methoxyquinazolin-6-yloxy)-Nhydroxyheptanam ide (CUDc-101) as potent multi-acting HDAC EGFR and HER2 inhibitor for the treatment of cancer. J Med Chem 2010;53:2000-9
172. Miller TA, Witter DJ, Belvedere S. Histone deacetylase inhibitors. J Med Chem 2003;46:5097-116 (Pubitemid 37414179)
173. Curis, Inc. Quinazoline based EGFR inhibitors containing a zinc binding moiety. WO2008033748; 2008
174. Curis, Inc. Quinazoline based EGFR inhibitors containing a zinc binding moiety. WO2008033749; 2008
175. Lai CJ, Bao R, Tao X, et al. CUDC- 101, a multitargeted inhibitor of histone deacetylase, epidermal growth factor receptor, and human epidermal growth factor receptor 2, exerts potent anticancer activity. Cancer Res 2010;70:3647-56
176. Available from: www.clinicaltrial.gov NCT01384799
177. Curis, Inc. Tartrate salts or complexes of quinazoline based EGFR inhibitors containing a zinc binding moiety. WO2009035718; 2009
178. Curis, Inc. Antiproliferative agents containing a zinc binding moiety. WO2009036057; 2009
179. Angion Biomedica. Modulators of hepatocyte growth factor/c-Met activity. WO2007081978; 2007
180. AstraZeneca AB. Quinazoline derivatives. WO2007099317; 2007
181. Bayer Schering Pharma. Quinazoline derivatives, their preparation, their use as tyrosine kinase inhibitors and medicaments comprising them. WO2007147577; 2007
182. Irm Llc. Protein kinase inhibitors and methods for using thereof. WO2008157575; 2008
183. Bayer Schering Pharma. Novel sulphoximine-substituted quinazoline and quinazoline derivatives as kinase inhibitors. WO2008141843; 2008
184. Natco Pharma. Novel 4-(tetrazol-5-yl) quinzoline derivatives as anticancer agents. WO2009057139; 2009
185. Natco Pharma. 6,7-Dialkoxy quinazoline derivatives useful for treatment of cancer related disorders. WO2009090661; 2009
186. Freie Universitat Berlin. Substituted 4- (indol-3-yl)quinazolines and use and production thereof. WO2009103719; 2009
187. Hutchison Medipharma Enterprises Ltd. Quinazoline derivatives. WO2009137797; 2009
188. Fovea Pharmaceuticals. Substituted quinazoline compounds. WO2010076238; 2010
189. Ambit Biosciences Corp. Jak kinase modulating quinazoline derivatives and methods of use thereof. WO2010099379; 2010
190. Hutchson Medipharma Enterprises Ltd. Quinazoline derivatives. WO2010002845; 2010
191. Fridman JS, Lowe SW. Control of apoptosis by p53. Oncogene 2003;22:9030-40 (Pubitemid 38121703)
192. Vogelstein B, Lane D, Levine AJ. Surfing the p53 network. Nature 2000;408:307-10
193. Auckland Uniservices Ltd. Substituted ring fused azines and their use in cancer therapy. WO2007117161; 2007
194. Schering Corp. Quinazoline derivatives useful in cancer treatment. WO2007011623; 2007
195. Demma M, Maxwell E, Ramos R, et al. SCH529074, a small molecule activator of mutant p53, which binds p53 DNA binding domain (DBD), restores growth-suppressive function to mutant p53 and interrupts HDM2-mediated ubiquitination of wild type p53. J Biol Chem 2010;285:10198-212
196. Auspex Pharmaceuticals. Diaminoquinazoline inhibitors of dihydrofolate reductase. WO2010068920; 2010
197. BTG International Ltd. Cyclopenta[g] quinazoline derivatives for the treatment of rheumatoid arthritis or acute myeloid leukaemia. WO2009115776; 2009
198. Theti DS, Bavetsias V, Skelton LA, et al. Selective delivery of CB300638, cyclopenta[g]quinazoline-based thymidylate synthase inhibitor into human tumor cell lines overexpressing the alpha-isoform of the folate receptor. Cancer Res 2003;63:3612-18 (Pubitemid 36793043)
199. Gibbs DD, Theti DS, Wood N, et al. BGC 945, a novel tumor-selective thymidylate synthase inhibitor targeted to alpha-folate receptor-overexpressing tumors. Cancer Res 2005;65:11721-8
200. Henderson EA, Bavetsias V, Theti DS, et al. Targeting the alpha-folate receptor with cyclopenta[g]quinazoline-based inhibitors of thymidylate synthase. Bioorg Med Chem 2006;14:5020-42 (Pubitemid 43767126)
201. President and Fellows of Harvard College. Compounds and methods for enzyme-mediated tumor imaging and therapy. WO2008069976; 2008
202. Smith JC. Hedgehog, the floor plate, and the zone of polarizing activity. Cell 1994;76:193-6 (Pubitemid 24046680)
203. Rubin LL, de Sauvage FJ. Targeting the Hedgehog pathway in cancer. Nat Rev Drug Discov 2006;5:1026-33 (Pubitemid 44835129)
204. Exelixis. Inhibitors of the hedgehog pathway. WO2008112913; 2008
205. Abraxis Bioscience. Isoquinoline, quinoline and quinazoline derivatives as inhibitors of hedgehog signalling. WO2010144586; 2010
206. Nelson WJ, Nusse R. Convergence of Wnt, beta-catenin, and cadherin pathways. Science 2004;303:1483-7 (Pubitemid 38314410)
207. Kinzler KW, Vogelstein B. Lessons from hereditary colorectal cancer. Cell 1996;87:159-70 (Pubitemid 26358996)
208. Wyeth. Amino-substituted quinazoline derivatives as inhibitors of beta-catenin/ TCF-4 pathway and cancer treatment agents. WO2008086462; 2008
209. Chen Z, Venkatesan AM, Dehnhardt CM, et al. 2,4-Diaminoquinazolines as inhibitors of beta-catenin/ Tcf-4 pathway: potential treatment for colorectal cancer. Bioorg Med Chem Lett 2009;19:4980-3
210. Dehnhardt CM, Venkatesan AM, Chen Z, et al. Design and synthesis of novel diaminoquinazolines with in vivo efficacy for beta-catenin/T-cell transcriptional factor 4 pathway inhibition. J Med Chem 2010;53:897-910
211. The Government of the USA. Low molecular weight thyroid stimulating hormone receptor (TSHR) agonists. WO2010047674; 2010
212. Neumann S, Huang W, Titus S, et al. Small-molecule agonists for the thyrotropin receptor stimulate thyroid function in human thyrocytes and mice. Proc Natl Acad Sci USA 2009;106:12471-6
213. Srivastava V, Gupta SP, Siddiqi MI, Mishra BN. 3D-QSAR studies on quinazoline antifolate thymidylate synthase inhibitors by CoMFA and CoMSIA models. Eur J Med Chem 2010;45:1560-71
214. Marzaro G, Chilin A, Guiotto A, et al. Using the TOPS-MODE approach to fit multi-target QSAR models for tyrosine kinases inhibitors. Eur J Med Chem 2011;46:2185-92
215. Tanrikulu Y, Schneider G. Pseudoreceptor models in drug design: bridging ligand- and receptor-based virtual screening. Nat Rev Drug Discov 2008;7:667-77